Häfliger, Simon

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2018

2024

Bocchi, F; Häfliger, S; Schmid, S; Sidler, D (2024). Immune checkpoint inhibitors and renal toxicity. Heliyon, 10(11) Elsevier 10.1016/j.heliyon.2024.e31911

Schoenfeld, Adam J; Lee, Sylvia M; Doger de Speville, Bernard; Gettinger, Scott N; Hafliger, Simon; Sukari, Ammar; Papa, Sophie; Rodriguez-Moreno, Juan Francisco; Graf Finckenstein, Friedrich; Fiaz, Rana; Catlett, Melissa; Chen, Guang; Qi, Rongsu; Masteller, Emma L; Gontcharova, Viktoria; He, Kai (2024). Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. (In Press). Cancer discovery American Association for Cancer Research 10.1158/2159-8290.CD-23-1334

Colombo, Ilaria; Koster, Kira-Lee; Holer, Lisa; Haefliger, Simon; Rabaglio, Manuela; Bastian, Sara; Schwitter, Michael; Eckhardt, Katrin; Hayoz, Stefanie; Mc Laughlin, Anna M; Kloft, Charlotte; Klose, Marian; Halbherr, Stefan; Baumgartner, Christian; Sessa, Cristiana; Stathis, Anastasios; Hess, Dagmar; Joerger, Markus (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European journal of cancer, 201(113588), p. 113588. Elsevier 10.1016/j.ejca.2024.113588

Coan, Michela; Haefliger, Simon; Ounzain, Samir; Johnson, Rory (2024). Targeting and engineering long non-coding RNAs for cancer therapy. (In Press). Nature Reviews. Genetics Natue Publishing Group 10.1038/s41576-024-00693-2

2023

Wahli, Murielle N; Hayoz, Stefanie; Hoch, Dennis; Ryser, Christoph O; Hoffmann, Michèle; Scherz, Amina; Schwacha-Eipper, Birgit; Häfliger, Simon; Wampfler, Julian; Berger, Martin D; Novak, Urban; Özdemir, Berna C (2023). The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex. Journal of cancer research and clinical oncology, 149(7), pp. 3847-3858. Springer 10.1007/s00432-022-04309-2

Joerger, Markus; Hundsberger, Thomas; Haefliger, Simon; von Moos, Roger; Hottinger, Andreas F; Kaindl, Thomas; Engelhardt, Marc; Marszewska, Michalina; Lane, Heidi; Roth, Patrick; Stathis, Anastasios (2023). Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Investigational new drugs, 41(2), pp. 267-275. Springer 10.1007/s10637-023-01336-9

Bar, J; Peled, N; Schokrpur, S; Wolner, M; Rotem, O; Girard, N; Nana, F Aboubakar; Derijcke, S; Kian, W; Patel, S; Gantz-Sorotsky, H; Zer, A; Moskovitz, M; Metro, G; Rottenberg, Y; Calles, A; Hochmair, M; Cuppens, K; Decoster, L; Reck, M; ... (2023). UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN). Journal of thoracic oncology, 18(2), pp. 169-180. Elsevier 10.1016/j.jtho.2022.10.004

Frehner, Lorenz; Haefliger, Simon; Cerciello, Ferdinando; Grob, Tobias; Schmid, Sabine (2023). Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer. Case reports in oncology, 16(1), pp. 871-877. Karger 10.1159/000533572

2022

Vancura, Adrienne; Gutierrez, Alejandro H; Hennig, Thorben; Pulido-Quetglas, Carlos; Slack, Frank J; Johnson, Rory; Haefliger, Simon (2022). Is Evolutionary Conservation a Useful Predictor for Cancer Long Noncoding RNAs? Insights from the Cancer LncRNA Census 3. Non-Coding RNA, 8(6) MDPI 10.3390/ncrna8060082

Addeo, Alfredo; Rothschild, Sacha I; Holer, Lisa; Schneider, Martina; Waibel, Christine; Haefliger, Simon; Mark, Michael; Fernandez, Eugenio; Mach, Nicolas; Mauti, Laetitia; Jermann, Philip M; Alborelli, Ilaria; Calgua, Byron; Savic-Prince, Spasenija; Joerger, Markus; Früh, Martin (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung cancer, 172, pp. 154-159. Elsevier 10.1016/j.lungcan.2022.08.016

Esposito, Roberta; Polidori, Taisia; Meise, Dominik F; Pulido-Quetglas, Carlos; Chouvardas, Panagiotis; Forster, Stefan; Schaerer, Paulina; Kobel, Andrea; Schlatter, Juliette; Kerkhof, Erik; Roemmele, Michaela; Rice, Emily S.; Zhu, Lina; Lanzós, Andrés; Guillen-Ramirez, Hugo A; Basile, Giulia; Carrozzo, Irene; Vancura, Adrienne; Ullrich, Sebastian; Andrades, Alvaro; ... (2022). Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities. Cell genomics, 2(9), p. 100171. Elsevier 10.1016/j.xgen.2022.100171

Krebs, Fanny S; Britschgi, Christian; Pradervand, Sylvain; Achermann, Rita; Tsantoulis, Petros; Haefliger, Simon; Wicki, Andreas; Michielin, Olivier; Zoete, Vincent (2022). Structure-based prediction of BRAF mutation classes using machine-learning approaches. Scientific Reports, 12(1), p. 12528. Nature Publishing Group 10.1038/s41598-022-16556-x

2021

Vancura, Adrienne; Lanzós, Andrés; Bosch-Guiteras, Núria; Esteban, Mònica Torres; Gutierrez, Alejandro H; Haefliger, Simon; Johnson, Rory (2021). Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs. NAR cancer, 3(2), zcab013. Oxford University Press 10.1093/narcan/zcab013

2020

Häfliger, Simon; Seidel, Ann-Katrin; Schoch, Eric; Reichmann, Jan; Wild, Damian; Steinmann-Schwager, Stephanie; Pless, Miklos (2020). Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor. Case reports in oncology, 13(3), pp. 1373-1380. Karger 10.1159/000510334

2018

Tiede, Stefanie; Meyer-Schaller, Nathalie; Kalathur, Ravi Kiran Reddy; Ivanek, Robert; Fagiani, Ernesta; Schmassmann, Philip; Stillhard, Patrick; Häfliger, Simon; Kraut, Norbert; Schweifer, Norbert; Waizenegger, Irene C; Bill, Ruben; Christofori, Gerhard (2018). The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis, 7(9), p. 73. Springer Nature 10.1038/s41389-018-0083-1

Provide Feedback